Summit Global Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Summit Global Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Hold	4,436	–	–	0.01%	515
2026 Q1	$229K	Buy	4,436 +256	+6%	+$13K	0.01%	462
2025 Q4	$208K	Sell	4,180 -29	-0.7%	-$1.41K	0.01%	468
2025 Q3	$201K	Buy	+4,209	New	+$170K	0.01%	453
2023 Q2	–	Sell	-34,029	Closed	-$1.23M	–	614
2023 Q1	$1.23M	Buy	34,029 +15,629	+85%	+$601K	0.1%	203
2022 Q4	$656K	Buy	18,400 +100	+0.5%	+$3.48K	0.06%	269
2022 Q3	$619K	Sell	18,300 -17,200	-48%	-$560K	0.06%	272
2022 Q2	$1.03M	Buy	+35,500	New	+$1.02M	0.09%	214

Other funds holding SUPN

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

VIM

VELA Investment Management New Albany, Ohio $468M AUM 18.47% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Summit Global Investments's SUPN Position: Q2 2026 in Review

Summit Global Investments held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 4,436 shares worth $206K. The position accounts for 0.01% of the portfolio, ranked #515.

Summit Global Investments first reported a position in SUPN in Q2 2022 and has held it in 8 quarters since. The position peaked at $1.23M in Q1 2023. 88 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Summit Global Investments held 4,436 shares of Supernus Pharmaceuticals worth $206K as of Q2 2026.
Summit Global Investments left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
Supernus Pharmaceuticals made up 0.01% of Summit Global Investments's portfolio in Q2 2026, its #515 holding.
Summit Global Investments first reported a position in Supernus Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
Summit Global Investments's Supernus Pharmaceuticals position peaked at $1.23M in Q1 2023.
88 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.